Performance of a smell identification test versus the Mini-Mental Status Exam for the detection of dementia and cognitive impairment among persons with cognitive concerns in primary care
Restricted accessResearch articleFirst published online August, 2025
Performance of a smell identification test versus the Mini-Mental Status Exam for the detection of dementia and cognitive impairment among persons with cognitive concerns in primary care
Odor identification deficits predict Alzheimer's disease (AD) in epidemiological studies.
Objective
To compare the accuracy of a short odor identification test with a short cognitive screening test for the detection of dementia and cognitive impairment in elderly persons with cognitive concerns.
Methods
This was a cross-sectional study of 600 participants 65 years and older, without known mild cognitive impairment (MCI) or dementia, with cognitive concerns, attending primary care practices in New York City. The odor identification test was the Brief Smell Identification Test (BSIT). The comparator test was the Mini Mental Status Exam II (MMSE). Cognitive diagnoses were made using the National Alzheimer's Coordinating Center Uniform Data set (NACC-UDS) version 3 forms with slight modifications. Test performance was compared using Receiver Operating Characteristic analyses.
Results
The mean age was 72.65 ± 6.31 years, 73.3% were female, 63.3% were Hispanic, 13.5% non-Hispanic Black, and 20.8% non-Hispanic White; 23.5% were classified as normal cognition, 27.7% as cognitive impairment-not mild cognitive impairment (MCI), 31.2% as amnestic MCI, 5.7% as non-amnestic MCI, and 12% as dementia. The MMSE was superior to the BSIT in detecting dementia and any cognitive impairment. Combining abnormal scores in the BSIT (≤8) to MMSE (≤24) improved the MMSE's specificity and positive predictive value (PPV) in detecting cognitive impairment.
Conclusions
The MMSE was superior to the BSIT in detecting dementia and cognitive impairment in primary care but using both tests improved specificity and PPV for identifying persons with subjective complaints needing further cognitive and biomarker evaluation.
BradfordAKunikMESchulzP, et al.Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord2009; 23: 306–314.
8.
KotagalVLangaKMPlassmanBL, et al.Factors associated with cognitive evaluations in the United States. Neurology2015; 84: 64–71.
9.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
10.
NasreddineZSPhillipsNABedirianV, et al.The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
11.
TrzepaczPTHochstetlerHWangS, et al.Relationship between the Montreal cognitive assessment and Mini-mental state examination for assessment of mild cognitive impairment in older adults. BMC Geriatr2015; 15: 107.
12.
AlawodeDOTFoxNCZetterbergH, et al.Alzheimer’s disease biomarkers revisited from the amyloid cascade hypothesis standpoint. Front Neurosci2022; 16: 837390.
13.
CordellCBBorsonSBoustaniM, et al.Alzheimer's association recommendations for operationalizing the detection of cognitive impairment during the medicare annual wellness visit in a primary care setting. Alzheimers Dement2013; 9: 141–150.
14.
TalamoBRRudelRKosikKS, et al.Pathological changes in olfactory neurons in patients with Alzheimer's disease. Nature1989; 337: 736–739.
HymanBTArriagadaPVVan HoesenGW. Pathologic changes in the olfactory system in aging and Alzheimer's disease. Ann N Y Acad Sci1991; 640: 14–19.
17.
LiWHowardJDGottfriedJA. Disruption of odour quality coding in piriform cortex mediates olfactory deficits in Alzheimer's disease. Brain2010; 133: 2714–2726.
18.
DevanandDPLeeSManlyJ, et al.Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community. Neurology2015; 84: 182–189.
19.
DotyRLFryeREAgrawalU. Internal consistency reliability of the fractionated and whole university of Pennsylvania smell identification test. Percept Psychophys1989; 45: 381–384.
20.
AGS Clinical Practice Committee. Guidelines abstracted from the American academy of neurology's dementia guidelines for early detection, diagnosis, and management of dementia. J Am Geriatr Soc2003; 51: 869–873.
21.
HumesKRJonesNARamirezRR. Overview of race and Hispanic origin: 2010. Washington, DC: U.S. Department of Commerce, 2011.
22.
CharlsonMEPompeiPAlesKL, et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis1987; 40: 373–383.
23.
DevanandDPLiuXTabertMH, et al.Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry2008; 64: 871–879.
24.
DevanandDPTabertMHCuasayK, et al.Olfactory identification deficits and MCI in a multi-ethnic elderly community sample. Neurobiol Aging2010; 31: 1593–1600.
25.
TabertMHLiuXDotyRL, et al.A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol2005; 58: 155–160.
26.
DotyRLShamanPApplebaumSL, et al.Smell identification ability: changes with age. Science1984; 226: 1441–1443.
27.
MenonCWesterveltHJJahnDR, et al.Normative performance on the brief smell identification test (BSIT) in a multi-ethnic bilingual cohort: a project FRONTIER study. Clin Neuropsychol2013; 27: 946–961.
28.
HummelTKonnerthCGRosenheimK, et al.Screening of olfactory function with a four-minute odor identification test: reliability, normative data, and investigations in patients with olfactory loss. Ann Otol Rhinol Laryngol2001; 110: 976–981.
29.
AdlerGBrassenSChwalekK, et al.Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry2004; 75: 292–294.
30.
ArnoldSEHymanBTFloryJ, et al.The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex1991; 1: 103–116.
31.
Bahar-FuchsAChetelatGVillemagneVL, et al.Olfactory deficits and amyloid-beta burden in Alzheimer's disease, mild cognitive impairment, and healthy aging: a PiB PET study. J Alzheimers Dis2010; 22: 1081–1087.
32.
BraakHBraakE. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl1998; 53: 127–140.
33.
O'BryantSEHumphreysJDSmithGE, et al.Detecting dementia with the Mini-mental state examination in highly educated individuals. Arch Neurol2008; 65: 963–967.
34.
BesserLKukullWKnopmanDS, et al.Version 3 of the national Alzheimer's coordinating center's uniform data set. Alzheimer Dis Assoc Disord2018; 32: 351–358.
35.
BurkeWJRoccaforteWHWengelSP. The short form of the geriatric depression scale: a comparison with the 30-item form. J Geriatr Psychiatry Neurol1991; 4: 173–178.
36.
CummingsJL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology1997; 48: S10–S16.
37.
MorrisJC. The clinical dementia rating (CDR): current version and scoring rules. Neurology1993; 43: 2412-2412-a.
38.
WeintraubSBesserLDodgeHH, et al.Version 3 of the Alzheimer disease centers’ neuropsychological test battery in the uniform data set (UDS). Alzheimer Dis Assoc Disord2018; 32: 10–17.
39.
ManlyJJBell-McGintySTangMX, et al.Implementing diagnostic criteria and estimating frequency of mild cognitive impairment in an urban community. Arch Neurol2005; 62: 1739–1746.
40.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
41.
RomanGCTatemichiTKErkinjunttiT, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology1993; 43: 250–260.
42.
WalkerZPossinKLBoeveBF, et al.Lewy body dementias. Lancet2015; 386: 1683–1697.
43.
RascovskyKHodgesJRKnopmanD, et al.Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain2011; 134: 2456–2477.
44.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
45.
VexlerASchistermanEFLiuA. Estimation of ROC curves based on stably distributed biomarkers subject to measurement error and pooling mixtures. Stat Med2008; 27: 280–296.
46.
SchistermanEFFaraggiDReiserB, et al.Statistical inference for the area under the receiver operating characteristic curve in the presence of random measurement error. Am J Epidemiol2001; 154: 174–179.
47.
GreenlandS. The need for reorientation toward cost-effective prediction: comments on ‘evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond’ by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med2008; 27: 199–206.
48.
PencinaMJD’AgostinoRBSrD’AgostinoRBJr, et al.Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med2008; 27: 157–172; discussion 207–112.
49.
McNemarQ. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika1947; 12: 153–157.
50.
LachenbruchPALynchCJ. Assessing screening tests: extensions of McNemar's test. Stat Med1998; 17: 2207–2217.
51.
SchistermanEFFaraggiDReiserB, et al.Youden Index and the optimal threshold for markers with mass at zero. Stat Med2008; 27: 297–315.
52.
YoudenWJ. Index for rating diagnostic tests. Cancer1950; 3: 32–35.
53.
Hajian-TilakiK. Sample size estimation in diagnostic test studies of biomedical informatics. J Biomed Inform2014; 48: 193–204.
54.
BachmannLMPuhanMAter RietG, et al.Sample sizes of studies on diagnostic accuracy: literature survey. Br Med J2006; 332: 1127–1129.
55.
LiJFineJ. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Stat Med2004; 23: 2537–2550.
56.
YapACMahendranRKuaEH, et al.Olfactory dysfunction is associated with mild cognitive impairment in community-dwelling older adults. Front Aging Neurosci2022; 14: 930686.
57.
de BruijnRFAkoudadSCremersLG, et al.Determinants, MRI correlates, and prognosis of mild cognitive impairment: the rotterdam study. J Alzheimers Dis2014; 42(Suppl 3): S239–S249.
58.
DevanandDPLeeSLuchsingerJA, et al.Intact global cognitive and olfactory ability predicts lack of transition to dementia. Alzheimers Dement2020; 16: 326–334.
59.
ChanMLMeyerOLFariasST, et al.APOE Effects on late life cognitive trajectories in diverse racial/ethnic groups. J Int Neuropsychol Soc2023; 29: 126–135.
60.
DotyRL. Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate?Lancet Neurol2017; 16: 478–488.
61.
MotterJNChoiJLeeS, et al.Association of performance on olfactory and cognitive screening tests with conversion to dementia in a biracial cohort of older adults. Neurology2023; 101: e1046–e1055.
62.
DevanandDPLeeSLuchsingerJA, et al.Comparison of brief olfactory and cognitive assessments to neuroimaging biomarkers in the prediction of cognitive decline and dementia in the MCSA cohort. Alzheimers Dement2024; 20: 8346–8358.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
